A 42-year-old woman from Delhi presents with postmenopausal bleeding for 3 months. On examination, a 4 cm friable, bleeding cervical mass is noted. Pap smear shows HSIL (High-Grade Squamous Intraepithelial Lesion). HPV testing is positive for HPV-16. What is the most appropriate next step in management?

Explanation

## Management of a Visible Cervical Mass with Suspected Invasive Cancer **Key Point:** When a **clinically visible cervical lesion** is present (as in this case — a 4 cm friable, bleeding mass), the immediate next step is **tissue biopsy for histological confirmation** before staging or treatment planning. Colposcopy-guided (or direct punch) biopsy provides the definitive tissue diagnosis required to confirm invasive carcinoma. ### Why Biopsy First? - A **Pap smear showing HSIL** is a cytological (not histological) finding — it cannot confirm invasion - **Staging investigations** (MRI, CT, tumour markers) are only initiated **after histological confirmation** of invasive cervical cancer - Without tissue diagnosis, staging and treatment planning are premature - **FIGO guidelines (2023)** and **NCCN Cervical Cancer Guidelines (2023)** both mandate histopathological confirmation before staging ### Clinical Clues in This Case | Feature | Significance | |---|---| | 4 cm friable, bleeding cervical mass | Clinically suspicious for invasive carcinoma | | Postmenopausal bleeding | Raises concern for invasive disease | | HSIL on Pap smear | Cytological precursor finding — not diagnostic of invasion | | HPV-16 positive | High-risk HPV type strongly associated with invasive SCC | ### Why Not the Other Options? - **Option B (Staging investigations):** Staging is the correct *subsequent* step, but only after histological confirmation of invasive cancer. Staging without a tissue diagnosis is not appropriate. - **Option C (Excisional cone biopsy):** Cone biopsy is used for diagnosis/treatment of CIN or microinvasive disease (FIGO IA1). For a 4 cm gross lesion, cone biopsy is inappropriate and potentially harmful. - **Option D (Repeat Pap smear after 3 months):** Completely inappropriate — a visible 4 cm mass requires immediate tissue diagnosis, not cytological surveillance. ### Correct Sequence of Management ``` Visible cervical mass ↓ Colposcopy-guided / direct punch biopsy (office procedure) ↓ Histological confirmation of invasive carcinoma ↓ Staging investigations (MRI pelvis, CT chest/abdomen, SCC-Ag) ↓ FIGO staging → Treatment planning (surgery vs. chemoradiation) ``` **Clinical Pearl:** Colposcopy-guided biopsy is appropriate for **both visible and non-visible lesions** when histological confirmation is needed. For a grossly visible lesion, direct punch biopsy under visualization (with or without colposcopy) is the standard first step. Staging must never precede tissue diagnosis. **High-Yield:** Per NCCN and FIGO 2023 guidelines, **histological confirmation is mandatory** before initiating staging workup or definitive treatment for cervical cancer. [cite: FIGO Cervical Cancer Staging Guidelines 2023; NCCN Clinical Practice Guidelines in Oncology — Cervical Cancer v1.2023; Berek & Hacker's Gynecologic Oncology, 7th ed.]